Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Obesity negatively affects pulmonary vein isolation outcomes in drug-refractory AF

14 Jun 2018

Among patients with drug-refractory atrial fibrillation (AF), obesity is associated with lower pulmonary vein isolation (PVI) treatment success but not with increased adverse events, as reported in a study.

Researchers looked at 414 consecutive patients (mean age 56 years; 76 percent male) who underwent transcatheter PVI for AF between. PVI was considered successful if patients did not show atrial arrhythmia on Holter monitoring or ECG, with or without antiarrhythmic drugs during follow-up.

Of the patients, 311 (75 percent) had paroxysmal AF and 111 (27 percent) were obese (body mass index [BMI] ≥30 kg/m²). Mean duration of follow-up was 46 months.

Freedom from atrial arrhythmia and antiarrhythmic drugs occurred more frequently in nonobese vs obese patients (46 percent vs 30 percent; p=0.005). The same was true for the outcome of freedom from atrial arrhythmia but not antiarrhythmic drugs (68 percent vs 56 percent; p=0.036).

Minor and major adverse events (AEs), on the other hand, did not differ between patients with and without obesity (major AEs: 6 percent vs 3 percent, respectively; p=0.105; minor AEs: 5 percent vs 5 percent; p=0.512).

Sensitivity analyses revealed an association between BMI (as continuous variable) and PVI outcome (hazard ratio, 1.08; 95 percent CI, 1.02–1.14; p=0.012).

The present data highlight the importance of risk factor management, including weight loss, in patients with symptomatic AF before invasive treatment modalities are deployed, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.